AVATR received the approval for starting a new trial in Valle d'Aosta at the Umberto Parini Hospital, where the AVATR platform will be used to drive the remote of care of patients that have been affected by COVID-19 disease and can develop Cardio Vascular Diseases in the following months.

AVATR technology have been shortlisted by SWITCH (Singapore Week of Innovation and Technology) as one of the top 10 startups helping to combat the current global pandemic. This is recognition of the impact our technology delivers for populations at risk and suffering from chronic disease – namely through remote monitoring and a macro dashboard for global analysis within large cities.

AVATR has been selected as one of the 16 "Game Changers" of the COVID-X EU-funded project (https://www.covid-x.eu/game-changers/). In collaboration with the University of Catanzaro (as clinical partner), AVATR will develop the MADCAP (Management and Assessment of coviD for Chronic diseAse Patients) project. MADCAP targets cardiovascular disease patients diagnosed with COVID-19 aiming to support their remote care. The scalable solution gives remote support for COVID-19 risk management for prevention of infection, for managing remote treatments and for dealing with infection and post-infection cases. Gathering clinical and contextual patient data, it will support doctors to improve the care process.

AVATR and Imperial College NHS aim to develop highly personalised, contextual and culturally-sensitive outpatient services for patients at risk of CHD, diabetes and COVID-related complications. This is a significant step in AVATR’s mission to deliver personalised and culturally competent healthcare using AI.

AVATR engineers and designers are now working collaboratively with St. Bartholomew's Hospital clinicians to co-develop AVATR services to support the rehabilitation of South Asian cardiac patients. The ultimate objective is to engage patients as partners in their healthcare.

This is a very exciting opportunity within the NHS that builds on AVATR AI capability to deliver highly personalised and contextualised healthcare in the community, in collaboration with Queen Mary University of London.

As part of our medical study in Brazil, AVATR has been deployed at São Paulo University Hospital InCor, for patients suffering from Hypertension. In the context of COVID this will reduce the burden on the medical team, who will be monitoring of the patients remotely. It will also allow them to update their patient care plan and protocols without bringing them to the hospital, reducing the risk of spreading COVID-19.

Our first randomised medial trial is starting in the UK, focusing on patients suffering from obesity and atrial fibrillation. The patient onboarding phase has started. The study aims to demonstrate that the patient engagement provided through AVATR will help reduce health risks and improve the quality of life, freeing up time and resources for the medical teams.

AVATR was awarded the prestigious European Commission Seal of Excellence, based on the quality of the technology. With this accreditation, Inavya is well-positioned to receive fresh opportunities for AVATR. In fact, and despite challenges related to the COVID-19 pandemic, we have continued development with direct engagement of clinical teams globally.

Thanks to the funding from the Calabria Region, AVATR srl will have the possibility to improve the AVATR technologies with addition AI components and prototyping a Blockchain-based infrastructure and start preparing the launch of AVATR in the Italian market.

AVATR srl has been selected as one of the Italian startup that will participate to the 1st edition of the Global Startup Programme organised by ICE. After an initial tutoring period, AVATR srl will spend 6 months at the Entrepreneurs Roundtable Accelerator (ERA) of New York and Boston.